Korean Cancer Study Group
- Country
- 🇰🇷South Korea
- Ownership
- -
- Established
- 1998-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.kcsg.org/
Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Korean Cancer Study Group
- Target Recruit Count
- 40
- Registration Number
- NCT05079503
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Korean Cancer Study Group
- Target Recruit Count
- 48
- Registration Number
- NCT04761744
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Seongbuk-gu, Inchon-ro, Korea, Republic of
🇰🇷Korean Cancer Study Group, Seoul, Chongro-ku, Korea, Republic of
Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients
- Conditions
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Korean Cancer Study Group
- Target Recruit Count
- 65
- Registration Number
- NCT04753203
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Korean Cancer Study Group
- Registration Number
- NCT04751955
Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Korean Cancer Study Group
- Target Recruit Count
- 15
- Registration Number
- NCT03698383
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Korean Cancer Study Group
- Target Recruit Count
- 44
- Registration Number
- NCT01741116
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Seongbuk-gu, Inchon-ro, Korea, Republic of
🇰🇷Korean Cancer Study Group, Seoul, Chongro-ku, Korea, Republic of
Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2010-10-20
- Lead Sponsor
- Korean Cancer Study Group
- Target Recruit Count
- 518
- Registration Number
- NCT01224652
- Locations
- 🇰🇷
Yonsei University Gangnam Severance Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Paclitaxel and Cisplatin for Thymic Neoplasm
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- Korean Cancer Study Group
- Target Recruit Count
- 39
- Registration Number
- NCT00818090
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer
- Conditions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2010-05-26
- Lead Sponsor
- Korean Cancer Study Group
- Target Recruit Count
- 44
- Registration Number
- NCT00343668
- Locations
- 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun-gun, Jeolanam-do, Korea, Republic of
🇰🇷Inha University hospital, Inchon, Korea, Republic of
🇰🇷Chonbuk National University Hospital, Jeonju, Jeonbuk, Korea, Republic of